FIXX News and Press, Homology Medicines Inc. From 11/12/19

Expects to Report Initial Clinical Data from Phase 1/2 pheNIX PKU Gene Therapy Clinical Trial by Year-End Presented Preclinical Data Demonstrating Progress in MLD Gene Therapy and PKU Gene Editing Programs BEDFORD, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc...

Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BEDFORD, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the oral presentation of preclinical data related to its nuclease-free, homologous recombination-based, in vivo gene editing program for phenylketonuria ...

BEDFORD, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its investigational gene therapy programs for the treatment of metachromatic leukodystrophy (MLD) and phe...

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...

BEDFORD, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations at the following industry, investor and scientific conferences: 2019 Cell & Gene Meeting on the Mesa at the Park Hyatt Aviara Resort ...

BioMarin Pharmaceutical ( BMRN -0.5% ) has submitted an application to UK regulators seeking signoff to launch a Phase 1/2 clinical trial evaluating a single administration of BMN 307 in patients with phenylketonuria (PKU), a rare inborn error of metabolism that causes the amino acid phe...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $14 (141% upside) price target at Oppenheimer. Shares up  4%  premarket. More news on: Aurinia Pharmaceuticals Inc., Homology Medicines, Inc., IDEAYA Biosciences, Inc., Healthcare stocks news, Stocks on ...

Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...

BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming investor conferences. Citi’s 14 th Annual Biotech Conference Four Seasons Hotel, Bos...